Company intelligence / Profile preview
t2cure
Frankfurt am Main, Hesse, Germanyt2cure.de ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
t2c001, an autologous cellular therapeutic derived from patients' own bone marrow, received orphan drug designation for Buerger’s Disease and has shown promising clinical benefits in pilot studies. The product has successfully passed Phase II and is commercially available in Germany for patients with myocardial infarction.
- Therapeutic areas
- Cardiovascular
- Modalities
- Cell therapyStem cell therapyAutologous cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Johann Wolfgang Goethe-Universität Frankfurt am Main (originator for some programs)
Beyond the preview
Go deeper on t2cure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on t2cure.